Inflammation and Parkinsons Disease
The DOI matches its Crossref record.
Abstract
Numerous recent findings indicate the possible involvement of an immune mechanism in the pathogenesis of neurodegeneration. The immune reaction could either act as a primary event, generating changes leading to cell death, or could be a secondary response to neuronal injury. In various neurodegenerative disorders such as Alzheimer's, Huntington's or Pick's disease, Down's syndrome, multiple sclerosis and the AIDS-dementia complex, the inflammatory pathomechanism is strongly supported by experimental and clinical studies. Such inflammatory mechanisms have also been postulated in Parkinson's disease (PD). This review summarizes some generalities about inflammation and immune reactions in the context of the brain, and provides clinical, epidemiological and experimental data showing that inflammation and immunity, or even auto-immunity, could be implicated in PD, either in its initial step or in its progression. Different experimental models useful for studying the role(s) of inflammation and (auto)immunity in the neurodegenerative process of the dopaminergic neurons in PD are examined. The major similarities and differences between PD and other neurodegenerative disorders are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease
Turner, M. D., Nedjai, B., Hurst, T., & Pennington, D. J. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.05.014 · Cited by 2,162
Tansey, M. G., & Goldberg, M. S. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.004 · Cited by 1,045
“…A and FK-506 (tacrolimus) as well as the non-immunosuppressant derivatives of FK-506 referred to as immunophilin ligands including pentoxifylline (Wersinger and Sidhu, 2002; Liu and Hong, 2003), and the nonselective COX-2 inhibitor sodium salicylate have all shown neuroprotective activity in…”
BackgroundTansey, M. G., McCoy, M. K., & Frank-Cannon, T. C. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.07.004 · Cited by 583
Parkin Deficiency Increases Vulnerability to Inflammation-Related Nigral Degeneration
Frank-Cannon, T. C., Tran, T., Ruhn, K. A., Martinez, T. N., Hong, J., Marvin, M., Hartley, M., Treviño, I., O'Brien, D. E., Casey, B., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3001-08.2008 · Cited by 261
Morris, G. P., Clark, I. A., Zinn, R., & Vissel, B. (2013) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2013.07.002 · Cited by 236
Deleterious Effects of Minocycline in Animal Models of Parkinson’s Disease and Huntington’s Disease
Diguet, E., Fernagut, P., Wei, X., Du, Y., Rouland, R., Gross, C., Bezard, E., & Tison, F. (2004) · European Journal of Neuroscience · doi:10.1111/j.0953-816x.2004.03372.x · Cited by 189
Intercellular (Mis)communication in Neurodegenerative Disease
Garden, G. A., & La Spada, A. R. (2012) · Neuron · doi:10.1016/j.neuron.2012.02.017 · Cited by 170
Kawahata, I., Tokuoka, H., Parvez, H., & Ichinose, H. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0304-z · Cited by 31
“…system, which would induce an accumulation and aggregation of cytoplasmic proteins, may play a major role in the pathogenesis of both familial and sporadic forms of PD (McNaught et al. 2001; McNaught and Olanow 2003), perhaps mediated by cellular inflammation (Wersinger and Sidhu 2002).”
Background
Metadata
- Authors
- Wersinger, C., & Sidhu, A.
- Venue
- Current Drug Target -Inflammation & Allergy
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2002-09-01
- Volume
- 1
- Issue
- 3
- Pages
- 221-242
- ISSN
- 1568-010X (ISSN-L)
- OpenAlex
- W1544085379
- Cited by
- 45
- References
- 0
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.